The DOI matches its Crossref record.
Promising New Treatment Schedule for Gefitinib Responders After Severe Hepatotoxicity With Daily Administration
Abstract
assessing depression in a considerable proportion of patients, we based our conclusion on the HADS: depressed mood was associated with an increased likelihood of requesting euthanasia.In our discussion we add that depressed mood as assessed by the HADS has been shown to be predictive of the development of a clinical depression in cancer patients at the end of life.We are sure Scha ¨fer et al agree with us that we can draw the clinical conclusion that early detection of depressed mood is important for quality at the end of life for patients and their relatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In some instances, dose escalation may also increase the risk of developing idiosyncratic DILI as seen with azathioprine, whereas dose reduction or increasing the dosing interval may improve tolerability.35–37”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 8
- 10.1200/JCO.2004.00.6650 · DOI
- 10.1200/JCO.2002.10.112 · DOI · Paper page
- 10.1093/annonc/mdg250 · DOI · Paper page
- 10.1200/JCO.2002.03.100 · DOI · Paper page
- 10.1200/JCO.2002.03.038 · DOI · Paper page
- 10.1200/JCO.2003.10.038 · DOI · Paper page
- 10.1093/jnci/dji112 · DOI · Paper page
- 10.1001/jama.290.16.2149 · DOI · Paper page
Cited by
Drug-induced liver injury: Interactions between drug properties and host factors
Chen, M., Suzuki, A., Borlak, J., Andrade, R. J., & Lucena, M. I. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.016 · Cited by 405
Overview of current systemic management of EGFR-mutant NSCLC
Hsu, W.-H., Yang, J. C.-H., Mok, T. S., & Loong, H. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx702 · Cited by 388
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Shah, R. R., Morganroth, J., & Shah, D. R. (2013) · Drug Safety · doi:10.1007/s40264-013-0048-4 · Cited by 252
Metadata
- Authors
- Seki, N., Uematsu, K., Shibakuki, R., & Eguchi, K.
- Affiliations
- Division of Medical Oncology, Tokai University School of Medicine, Kanagawa, Japan
- Division of Diagnostic Pathology, Tokai University School of Medicine, Kanagawa, Japan
- Venue
- Journal of Clinical Oncology
- Published
- 2006-07-01
- Volume
- 24
- Issue
- 19
- Pages
- 3213-3214
- ISSN
- 0732-183X
- 1527-7755
- Cited by
- 31
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Promising New Treatment Schedule for Gefitinib Responders After Severe Hepatotoxicity With Daily Administration. https://app.cochat.ai/papers/10.1200/jco.2006.05.7109
- The paper
- Seki, N., Uematsu, K., Shibakuki, R., & Eguchi, K. (2006). Promising New Treatment Schedule for Gefitinib Responders After Severe Hepatotoxicity With Daily Administration. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.05.7109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.